Evaluating the Safety and Tolerability of an Additional Dose of Rimegepant for Adults with Migraine

What this Trial Is About

Researchers are evaluating the safety and tolerability of taking an additional dose of rimegepant for adults experiencing migraine attacks. This study focuses on adults with a history of migraine who may need a second dose of the medication for residual pain or headache relapse after an initial dose. The study is designed to follow participants over a 24-week period to understand how safe and tolerable repeated doses are in this context. Participants will receive rimegepant 75 mg orally disintegrating tablets ODT to treat migraine attacks of moderate or severe pain. If participants are not pain free about 2 hours after the first dose or if the headache returns after initial relief, they may take a second 75 mg dose within 24 hours. This redosing option can be used up to 10 times per month during the 24-week open-label treatment phase. During the study, participants will be monitored for treatment-emergent adverse events and liver function test changes related to dosing frequency. Patient satisfaction with headache pain reduction and impact on daily activities will also be assessed. The study includes regular evaluations over the 24-week period to track safety, tolerability, and effectiveness of redosing rimegepant for acute migraine treatment.

A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine